Seric Calprotectine in Spondyloarthritis

Centre Hospitalier Universitaire de Nice

Status: Completed

Conditions: Spondylarthritis

Treatments: Other: blood sampling

Study type: Observational

Funder types: Other

Identifiers

NCT03818958

17-COLL-04

Details and patient eligibility

About

To date, there are no biomarkers in spondyloarthritis that can differentiate between spondyloarthritis and fibromyalgia or other pathologies. Fecal calprotectin is a biomarker that is increasingly used in inflammatory diseases of the digestive tract. A growing interest in this biomarker is emerging in rheumatology, several publications have focused on its interest in rheumatoid arthritis, highlighting an association between serum calprotectin levels and disease activity. In spondyloarthritis, a few studies seem to show that it could be a marker of disease activity. Although a 2012 study found no difference in serum calprotectin levels between subjects with spondyloarthritis and controls. Still others have shown that it could be a predictive factor of radiological evolution in the same disease key. These data support, despite the questionable results of the Klingberg study, the value of this dosage in spondyloarthritis. The objective of this work is to show that this assay could be useful to differentiate spondyloarthritis from other pathologies with similar clinical presentation such as fibromyalgia. Difficulties classically encountered in common practice in rheumatology.

Enrollment: 1,000 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Patients in the active line of the rheumatology department with one of the following criteria:

  • active spondyloarthritis (BASDAI >4),
  • or spondyloarthritis in low activity (BASDAI<4),
  • or fibromyalgia without associated inflammatory rheumatism,
  • or healthy subjects (without inflammatory rheumatism and without fibromyalgia.

• Patients who have not objected to the use of their samples

Exclusion criteria

• Minor patient
• Subject not affiliated to the social security system
• Subject deprived of liberty
• Patient under guardianship or curatorship

Trial design

1,000 participants in 4 patient groups

active spondyloarthritis

Description:

subjects with active spondyloarthritis with a BASDAI greater than 4

Treatment:

Other: blood sampling

remission spondyloarthritis

Description:

subjects presenting with a remission spondyloarthritis defined by a BASDAI less than 4

Treatment:

Other: blood sampling

controls without spondyloarthritis

Description:

controls without spondyloarthritis or other chronic inflammatory rheumatism and without fibromyalgia

Treatment:

Other: blood sampling

fibromyalgia

Description:

subjects with fibromyalgia

Treatment:

Other: blood sampling